Information Provided By: 
Fly News Breaks for October 15, 2018
ACRX
Oct 15, 2018 | 08:45 EDT
Cantor Fitzgerald analyst Brandon Folkes raised his price target for AcelRx to $8 citing increased conviction that Dsuvia will be approved by the FDA on its November 3 action date following Friday's positive panel vote. AcelRx could have two product approvals within the next 12 months, along with the potential to launch or partner Dsuvia in Europe after approval earlier this year, Folkes tells investors in a research note. He believes upward earnings revisions will drive upside momentum in the stock and reiterates an Overweight rating on the name.
News For ACRX From the Last 2 Days
There are no results for your query ACRX
